Naar homepage     
Chronische Cerebro-Spinale Veneuze Insufficiëntie
Aanmelden op het CCSVI.nl forum
Lees Voor (ReadSpeaker)    A-   A+
Over CCSVI.nl | Zoeken | Contact | Forum
CCSVI.nl is onderdeel van de
Franz Schelling Website
meer informatie
  
Wednesday, November 3, 2010 1:09 AM | Ken Torbert Volg link

RESEARCH TOWARD RESTORING FUNCTION
-- CCSVI and MS


Two platform presentations and 14 posters focused on issues surrounding CCSVI (chronic
cerebrospinal venous insufficiency) and multiple sclerosis, presenting

mixed or conflicting results. In addition, the Charcot Foundation

convened a Satellite Symposium focused on CCSVI before the official

start of ECTRIMS, for which abstracts are not available.


The symposium featured formal short presentations by Drs. Paolo Zamboni
(Ferrara, Italy), Robert Zivadinov (Buffalo, New York), Florian Doepp

(Berlin, Germany), Omar Khan (Detroit, Michigan) and several others.

Among the issues raised were conflicting results from different groups,

the lack of “gold standards” for methodology or validated guidelines for

what constitutes vein abnormalities, disagreement about which imaging

technologies are optimum for evaluating variations in vein flow and

structure, and inconclusive results in terms of how or whether vein

abnormalities contribute to MS pathology. There was general agreement

from those on stage that invasive procedures to correct narrowing of the

veins should only be done in the context of controlled clinical trials.


The ECTRIMS presentations related to CCSVI are summarized here:


• In a platform presentation, Dr. Claudio Baracchini presented results

of a study at the University of Padua to investigate the prevalence of

CCSVI at the time of clinical onset of MS. The study involved 50

consecutive people who had clinically isolated syndrome (CIS, meaning

they had experienced a single neurological episode and had brain lesions

on MRI suggestive of MS, but for which there was insufficient evidence

to diagnose definite MS). Also included as controls were 50 age-matched

healthy controls, 50 people who had transient global amnesia (TGA), and

50 controls age-matched to those with transient global amnesia. All

underwent sonography of the veins in the brain (transcranial color-coded

venous sonography- TCCvS) and outside (extracranial color-coded venous

sonography - ECCVS) of the brain, and those who showed abnormalities in

sonography underwent venography. TCCvS was normal in all with CIS, and

abnormal ECCvS findings were found in 52% of CIS, in 32% of healthy

controls, and in 68% of TGA. Eight out of 50 CIS, or 16%, met CCSVI

criteria. Of those, venography was normal in 6, one had a hypoplasia

(incomplete development) of the right internal jugular vein, and one

developed tachycardia (rapid heart beat) and the exam was stopped.

(Abstract 81)


• In a platform presentation, Dr. Robert Zivadinov described a study at

the University of Buffalo using powerful 3T MRI

(“susceptibility-weighted imaging or SWI) of brain tissues (parenchyma)

and veins of 59 people with MS and 33 age and sex-matched healthy

controls to investigate the relationship between CCSVI and altered

visibility of the venous vasculature of the brain. Using Doppler

sonography, the team also determined that 79.7% of those with MS

fulfilled criteria for CCSVI, as did 18.2% of healthy controls. They

measured absolute venous volume (AVV) for total vein vasculature, and

relative venous intracranial fraction (VIF) to correct for head size and

brain atrophy. They also measured the size of individual veins, and

calculated “distance from vein maps,” with the higher distance

indicating lower density or fewer veins. They found that compared to

healthy controls, people with MS had lower AVV, lower volume of veins

with a diameter less than 0.3mm, higher distance from the veins, and

lower VIF. They found that this loss of smaller veins was related to

lower venous vasculature visibility and was linked with subjects that

fulfilled their criteria for CCSVI. They also found (perhaps

paradoxically, see Abstract P265 below) that the relationship between

altered vasculature and CCSVI was stronger for relapsing-remitting MS

than for secondary-progressive MS. (Abstract 82)


• Reporting in a poster (Abstract P321) on the same group of 59

patients and 33 age-matched controls, the Buffalo team found that

reduced venous vasculature visibility seen in people with MS was related

to changes in spinal fluid flow and hypoperfusion, or lower blood flow,

in the brain. In another poster related to the same group of 59

patients and controls, (Abstract P775), the team used conventional brain

MRI scans (with a 3T magnet) and found that reduced venous vasculature

visibility in MS was related to higher volume of T1-type lesions (these

types of MS plaques are thought to represent “black holes” or areas of

tissue destruction).


• In a study described in a poster (Abstract P324), Dr. M. P. Wattjes

and colleagues at the VU University Medical Center in Amsterdam examined

20 people with MS and 20 healthy controls using 3T magnetic resonance

venography (3D phase contrast angiography and multi-phase 3D

contrast-enhanced MR angiography) in an attempt to evaluate venous

obstructions using a technology that, unlike Doppler sonography,

provides consistent results which do not vary according to the

individual operator. Phase contrast MRI was used to quantify flow of the

internal cerebral veins and straight sinus. Images were analyzed by two

neuroradiologists who were blinded as to the status of the patients.

They found intracranial venous stenosis (narrowing) in 4 people with MS

and 1 healthy control. Extracranial stenosis was found in 8 MS patients

and 7 healthy controls, and no venous backflow was found in any patients

or controls.


• In several posters, more data was shared from a large-scale

prevalence study at the University of Buffalo involving 499 people,

including 289 people with MS, 21 people with CIS, 26 people with other

neurological disorders (OND) and 163 healthy controls. The team

reiterated previously released results suggesting that 54.8% of people

with MS fulfilled criteria for CCSVI, compared to 25.4% of the combined

controls. Further, they noted that CCSVI was more frequent in people

with progressive MS (69.6%) versus non-progressive MS (48.6%). For this

poster (Abstract P265), they evaluated whether there was any

relationship between a gene variation associated with increased MS

progression (HLA 1501) and the presence of CCSVI. They reported no

significant association between HLA 1501 and people with MS and CCSVI.


• In 70.3% of the same group of 499 people, the Buffalo team used

conventional MRI scans to evaluate differences in those meeting the

criteria for CCSVI and those who did not meet those criteria. Those

considered to have CCSVI were found to have a higher average number of

classic MS brain lesions (T2, thought to detect established, scarred

plaques) and also a higher average volume of T2 lesions than those

classified as not having CCSVI. Those with CCSVI also had signs of

having more brain atrophy, as measured by ventricle volume, parenchymal

volume and cortical volume, than those without CCSVI. (Abstract P318)

The team also evaluated clinical characteristics of the same group of

499 people (Abstract P653), reporting that CCSVI was more prevalent in

people with more advanced MS, ranging from 89.5% of those with relapsing

secondary-progressive MS to 49.2% in relapsing-remitting MS and 38.1%

of those with CIS. The team also reported that those meeting CCSVI

criteria tended to have more severe motor, cerebellar and brainstem

involvement.


• The Buffalo team presented a poster (Abstract P774) investigating the

presence of iron concentrations in the brain in 93 consecutive people

with MS and 51 age- and sex-matched healthy controls. Using Doppler

sonography they found that 66.7% of people with MS met criteria for

CCSVI, and 27.5% of healthy controls. They used MRI imaging to assess

venous insufficiency and susceptibility-weighted imaging of the deep

gray matter and found that those with CCSVI and MS who had the greatest

signs of venous insufficiency also had the highest concentrations of

iron in specific areas of the brain.


• Dr. Florian Doepp of Humboldt University in Berlin presented a poster

that expanded on his recently published findings in which the team was

unable to find evidence of CCSVI in MS in 56 people with MS and 20

controls, using extra- and transcranial Doppler sonography of veins and

blood flow. Expanding the study to 59 people with MS, the team confirmed

previous results, including that blood flow in the internal jugular

veins and vertebral veins was normal in all those tested except for one

patient. The team found that turning from the supine to the upright

position resulted in less pronounced decrease of total jugular blood

volume flow in people with MS, and suggested that future studies should

elucidate this difference seen in blood flow regulation. (Abstract P579)


• Dr. B. Yamout and colleagues at the American University of Beirut

reported in a poster (Abstract P663) a study using selective

extracranial venous angiography in 42 people with MS of varying duration

of disease; no controls were noted. Stenosis (narrowing) of at least

one vein was detected 24% of people classified as having early MS, and

in 92% of those classified as having late MS, with 7%, all in the late

MS group, having two veins blocked. They report that disease duration

was the strongest predictor of stenosis.


• Drs. K. Alikhani and M.C. Kremenchutzky presented a poster from the

MS Clinic in London, Ontario, studying the frequency of abnormal

magnetic resonance venography (MRV) of the great cervical veins in 46

people (21 with MS, 6 with CIS, 5 with possible MS, and 14 with non-MS).

They identified MRV abnormalities in 5 (23.8%) of those with MS, 3

(21.4%) of those with non-MS, in 1 with CIS, and none with possible MS.

The feature that most distinguished people with MS who had MRV

abnormalities was older age (average age of 54.8 years in those with

abnormal MRV, versus 44.14 years in those with normal MRV.) (Abstract

P778)


• In a poster presentation, Dr. Marian Simka and colleagues of

Katowice, Poland presented findings from 331 people with MS who had

previously been determined to meet criteria for CCSVI, who were

evaluated for duration and severity of MS, fatigue and other factors.

They found no correlation between the severity of venous obstacles and

age or duration of disease. They reported that those with narrowed

azygous veins tended to have the most aggressive clinical course. No

controls were noted. (Abstract P641)


• In another poster, Dr. Simka and colleagues reported on safety and

complications of endovascular procedures (balloon angioplasty and

stenting) in 347 people with MS and CCSVI whom they had treated. The

amount of followup time after the procedures was not provided. They

conducted 414 balloon angioplasties and 173 stent implantations during

361 interventions in 347 people with MS and CCSVI. Complications noted

included 2 cases of stent thrombosis, 1 case of surgical removal of a

balloon, 4 cases of bleeding from the groin, 1 case of minor

gastrointestinal bleeding, 2 cases of transient cardiac arrhythmia, 4

cases of difficulty removing balloon or its delivery system, 4 problems

with placement of stents, and 4 unsuccessful catheterization of the

stenosed internal jugular vein. (Abstract P914)


• Dr. Zamboni of the University of Ferrara, and colleagues from Italy

and the U.S., including the University of Buffalo, presented a poster

related to safety and tolerability of endovascular treatment

(percutaneous transluminal angioplasty, without stenting) for people

with MS meeting criteria for CCSVI. In this pilot study, 15 people who

remained on disease-modifying therapy were randomly assigned to two

treatment groups: 8 people received immediate treatment, and 7 received

treatment after a delay of 6 months. The treatment consisted of

selective venography and balloon dilation when stenoses (narrowing) were

detected, with followup imaging and clinical exams for 12 months. They

report that the treatment was well tolerated, and that no serious

adverse events occurred except one transitory vasovagal syndrome

(irregular heartbeat or faintness) one hour after treatment. Restenosis

occurred at a rate of 26.7%, exclusively in the jugular vein. They

conclude that further and larger studies are needed to determine the

effect of endovascular treatment for CCSVI in MS. (Abstract P508)


• Related to this treatment study, team members presented a poster

(Abstract P773) focusing on their use of different imaging techniques to

evaluate blood flow and narrowing of the internal jugular veins in 10

of the people treated as noted above and followed over 12 months, plus 6

healthy controls. They reported poor agreement of findings of stenosis

and flow between Doppler sonography and magnetic resonance venography.































http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=4057